Business Context and Reporting Period
This Form 8-K, filed on April 4, 2024, reports events occurring on April 9, 2024, for Illumina, Inc. (ILMN), a Delaware corporation headquartered in San Diego, California. The filing primarily addresses executive leadership changes and the reaffirmation of financial guidance.
Key Financial Metrics
This filing does not contain specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current or prior periods. It references guidance previously announced on February 8, 2024, but does not restate the numerical targets within this document.
Material Changes
- Executive Departure: Joydeep Goswami is stepping down as Chief Financial Officer (CFO) and Chief Strategy and Development Officer effective April 15, 2024. He will serve as an employee-advisor until June 30, 2024, before departing the company on July 1, 2024.
- Executive Appointment: Ankur Dhingra has been appointed as the new Chief Financial Officer, effective April 15, 2024. He will also serve as the principal financial officer for SEC filings starting on that date.
- Reason for Departure: The filing explicitly states that Mr. Goswami's departure is not the result of any disagreement regarding operations, financial reporting, policies, or practices.
Guidance, Outlook, and Compensation
Guidance Reaffirmation: On April 9, 2024, the Company issued a press release reaffirming its guidance for the first quarter and full-year 2024, consistent with the outlook provided during the Q4 2023 earnings call.
New CFO Compensation (Ankur Dhingra):
- Annual base salary: $650,000.
- Target variable cash bonus: 65% of base salary.
- One-time cash payment: $500,000 (subject to clawback provisions).
- One-time equity grant: $3,500,000 (70% PSUs, 30% RSUs).
- Relocation stipend: $15,000 per month until September 1, 2024, or relocation to San Diego.
Outgoing CFO Retention (Joydeep Goswami):
- Continued base salary during the retention period (April 15 – June 30, 2024).
- Lump sum payment of $360,000 upon successful completion of the retention period.
Investor Verification Checklist
- Verify the specific numerical values for Q1 and Full-Year 2024 guidance referenced in the April 9, 2024 press release (Exhibit 99.1).
- Review the transition plan details for the CFO role to ensure continuity in financial reporting and investor relations.
- Monitor the integration of Ankur Dhingra's background from Summit Therapeutics and Agilent Technologies into Illumina's strategic direction.
- Confirm the impact of the $3.5 million equity grant and $500,000 cash payment on near-term compensation expenses.